PML NUCLEAR BODIES · Function and regulation of promyelocytic leukemia (PML) nuclear bodies (NB) and their role in innate immunity and antiviral resistance
FP6 — Marie Curie Actions (Human Resources and Mobility)
- Duration
- 2004-12-01 → 2005-11-30
- EU contribution
- €40,000
- Participants
- 1
- Scheme
- ERG
Lines connect the coordinator with its partners.
Results in brief
Final Activity Report Summary - PML NUCLEAR BODIES (Function and regulation of promyelocytic leukemia (PML) nuclear bodies (NB) and their role in innate immunity and antiviral resistance)
The nucleus of a eukaryotic cell is the organelle where the genetic information is stored in the Deoxyribonucleic acid (DNA) and transcribed into Ribonucleic acid (RNA). Within the nucleus several discrete structures or sub-nuclear organelles exist and are involved in the regulation of gene expression, such as nucleoli, Cajal bodies, nuclear speckles and Promyelocytic leukemia (PML) bodies. Various characteristics were attributed to PML-bodies, including an active role in transcription, DNA repair, DNA replication, RNA, or a role as intranuclear protein depots. They were identified by the presence of the PML protein, which was essential for their formation because of its multimerisation and the subsequent recruitment of other proteins. In a special form of leukaemia, the PML-protein was fused to a transcription factor, leading to uncontrolled cells' proliferation and PML-bodies' dispersal. The PML protein also played a role in a number of human infectious diseases by viruses which needed the nuclear machinery of the host for their own replication. Infection with these viruses also led to dispersal of PML-bodies. The expression of the PML gene was highly up-regulated by interferons which pointed towards a function in innate immunity against infectious diseases. The assembly of PML-bodies was regulated by the covalent attachment of the Small ubiquitin-like modifier (SUMO) protein to PML. The SUMO conjugated form of PML then displayed binding sites for other proteins which were localised to PML bodies. Over 30 other proteins were found in PML-bodies so far, at least under certain conditions. The members of the Sp100 protein family were the best characterised out of these. Like PML, Sp100 was induced by interferons and could be modified by SUMO which regulated the binding to the heterochromatin binding proten 1 (HP1). Sp100 and the related proteins Sp110 and Sp140 contained DNA-binding domains and were found to function as transcriptional regulators of various genes, including certain viruses. Apart from these similarities in function and regulation, there was no evidence for a direct interaction between PML and Sp100. For most proteins, the mechanism of their recruitment into PML-bodies was unclear. In order to understand the assembly and regulation of PML-bodies and their antiviral activity, we studied the molecular interactions of the PML and Sp100 proteins. The complementary Deoxyribonucleic acids (cDNAs) of several PML-localised proteins and the enzymes involved in SUMO modification were cloned into bacterial expression vectors. We designed, based on these, a large number of deletion constructs around the previously characterised domains. The recombinant proteins were produced in bacteria and most of them could be isolated and purified in high yields. It turned out that all proteins comprising the N-terminal regions of the PML or Sp100 proteins had a strong tendency to form large complexes. These homotypic interactions of PML and Sp100 could also be shown by using the yeast-two hybrid system. Furthermore, we could analyse the binding of Sp100 to HP1 and the oligomerisation properties of Sp110 and Sp140. The interactions were verified by affinity purification of proteins from cell extracts with our recombinately produced proteins. In order to obtain these proteins in their SUMO conjugated form, we cloned the components of the SUMO modification enzyme cascade into commercially available co-expression vectors. The production of SUMO conjugated PML in bacteria could be demonstrated. With these modified proteins at hand we were then able to analyse the importance of the SUMO conjugation for the assembly of PML-bodies and their antiviral function.
Data: CORDIS, © European Union
Project objective
Promyelocytic leukemia (PML) nuclear bodies (NBs) are a sub-nuclear organelle implicated in various functions ranging from an active role in transcription, DNA repair, DNA replication and RNA transport, to a purely passive role as intra-nuclear depots for certain proteins. PML bodies are composed of several proteins and some of them can be strongly induced by interferons. The assembly of these proteins into NBs depends on the covalent modification by the protein SUMO. Several viral proteins localise to NBs but it is unclear whether these viruses use PML-bodies for their own replication or whether PML-bodies have a role in antiviral defence. This project aims to assess the function of PML-bodies by investigating the mechanism of their assembly. The starting point will be a detailed mapping of the interaction beween NB-associated proteins with biochemical and biophysical methods. In order to study the impact of the SUMO-modification on the assembly of PML-bodies a co-expression system will be established that allows the production of SUMO-modified proteins from in bacteria. The information on the assembly of PML-bodies will be verified in vivo using transfected cells and form the basis for a protocol to purify NBs from cells and tissues for further studies regarding their composition and function. The understanding of the function of PML-bodies will be a basis for the design of novel therapies against viral infectious diseases. The project will be funded by the interdisciplinary Centre for Molecular Medicine of the University of Cologne where Dr. Gerrit Praefcke being is going to establish an independent junior research group hosted by the Institute for Genetics. Funding includes initial equipment of the lab, positions for up to four staff and consumables for a duration of five years. After his training period of 2.5 years abroad this will enable Dr. Praefcke to work scientifically independent and to pursue an academic career in his home country.
Original text from CORDIS.
Participants
- KLINIKUM DER UNIVERSITAET ZU KOELN · KOELNCoordinatorGermany
Links
Data: CORDIS, © European Union
